Evotec SE: Video recording of Capital Markets Day presentations published

• CAPITAL MARKETS DAY: “SHAPING (NEW) MARKETS”, FEATURING PRESENTATIONS ON PANOMICS, IPSC & A.I./M.L. PLATFORMS FOR GROWTH AND ACCELERATED PIPELINE BUILDING
• VIDEO RECORDING OF ON-SITE EVENT AT EVOTEC’S HEADQUARTERS, MANFRED EIGEN CAMPUS IN HAMBURG, GERMANY, ON 15 NOVEMBER 2023 NOW AVAILABLE

Hamburg, Germany, 16 November 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announces that a video recording of the Capital Markets Day presentations is now available via this link.

Evotec’s second Capital Markets Day in 2023 was held on 15 November as an on-site event at the Company’s headquarters, Manfred Eigen Campus in Hamburg, Germany. Evotec’s Management and senior scientific staff illustrated how the Company is driving more efficient pipeline building towards assets, that are progressing with higher probabilities of success. Evotec’s platforms leverage novel A.I.-powered technologies that lead to new opportunities, higher capital efficiency, and ultimately improved patient outcomes and commercial success. 

The Capital Markets Day featured the following presentations:

• Welcome Message 
  Dr Claudia Karnbach, EVP, Global Head of Partnering, Site Head Hamburg
• Shaping new Markets: from disease understanding to pipeline building
  Dr Werner Lanthaler, Chief Executive Officer
• PanOmics: from patients for patients
  Dr Cord Dohrmann, Chief Scientific Officer
• E.MPD: pipeline building starts with better disease understanding
  Dr Olivier Radresa, SVP, Head of Nephrology
• EVOgnostics: better pipeline building needs better patient stratification
  Dr Christiane Honisch, SVP, Head of Diagnostics
• iPSC: Better pipeline building needs advanced disease modelling
  Dr Sandra Lubitz, SVP, iPSC
• Efficient pipeline building accelerating with A.I.
  Prof. Dr Bhushan Bonde, Head of Innovation for In-silico R&D
• Integrated platform for iPSC-based Therapeutics
  Dr Christine Günther, EVP, Head of Global Cell Therapy Translation
  Dr Andreas Scheel, EVP, Head of Cell Therapy
  Dr Markus Dangl, EVP, Head of Innovate Oncology

Evotec’s next Capital Markets Day will take place on 10 October 2024 at the Company’s Toulouse site “Campus Curie”, where the J.POD Toulouse, France (EU) is currently under construction.

FORWARD-LOOKING STATEMENTS 

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.